心脏淀粉样变性无创评估进展

doi:10.16138/j.1673-6087.2025.06.12

摘要/Abstract

摘要：

淀粉样变性是由于蛋白质错误折叠和沉积导致人体重要组织器官功能受损的一组疾病。系统性淀粉样变性常累及心脏，是淀粉样变性患者的主要死因。心脏淀粉样变确诊困难、预后不佳，早期诊断及评估对患者的治疗及预后至关重要。本文将对几种无创诊断评估心脏淀粉样变技术进行阐述。

关键词: 心脏淀粉样变性, 心脏磁共振, 心电图, 超声心动图, 放射性核素显像

Abstract:

Amyloidosis is a group of disorders caused by misfolded proteins that deposit in tissues and impair the function of vital organs. Systemic amyloidosis frequently involves the heart and is a leading cause of death in affected patients. Cardiac amyloidosis is difficult to diagnose and carries a poor prognosis, making early diagnosis and assessment crucial for treatment and prognosis. This article reviews several noninvasive techniques for diagnosing and evaluating cardiac amyloidosis.

Key words: Cardiac amyloidosis, Cardiac magnetic resonance, Electrocardiogram, Echocardiography, Radionuclide imaging

中图分类号:

R542.2

张茂森, 车子刚, 郭万华, 钟业鸣, 封成燕, 魏旋. 心脏淀粉样变性无创评估进展[J]. 内科理论与实践, 2025, 20(06): 495-499.

ZHANG Maosen, CHE Zigang, GUO Wanhua, ZHONG Yeming, FENG Chengyan, WEI Xuan. Progress in noninvasive assessment of cardiac amyloidosis[J]. Journal of Internal Medicine Concepts & Practice, 2025, 20(06): 495-499.

参考文献 37

[1]	Gertz MA, Dispenzieri A. Systemic amyloidosis recognition, prognosis, and therapy: a systematic review[J]. JAMA, 2020, 324(1):79-89. doi: 10.1001/jama.2020.5493
[2]	Bloom MW, Gorevic PD. Cardiac amyloidosis[J]. Ann Intern Med, 2023, 176(3):ITC33-ITC48. doi: 10.7326/AITC202303210
[3]	Garcia-Pavia P, Rapezzi C, Adler Y, et al. Diagnosis and treatment of cardiac amyloidosis. A position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases [J]. Eur J Heart Fail, 2021, 23(4): 512-526.
[4]	Gertz MA. Cardiac amyloidosis[J]. Heart Fail Clin, 2022, 18(3):479-488. doi: 10.1016/j.hfc.2022.02.005
[5]	Ioannou A, Patel RK, Martinez-Naharro A, et al. Tracking multiorgan treatment response in systemic AL-amyloidosis with cardiac magnetic resonance derived extracellular volume mapping[J]. JACC Cardiovasc Imaging, 2023, 16(8):1038-1052. doi: 10.1016/j.jcmg.2023.02.019
[6]	Lee C, Lam A, Kangappaden T, et al. Systematic literature review of evidence in amyloid light-chain amyloidosis[J]. J Comp Eff Res, 2022, 11(6):451-472. doi: 10.2217/cer-2021-0261
[7]	Muchtar E, Dispenzieri A, Magen, et al. Systemic amyloidosis from A (AA) to T (ATTR): a review[J]. J Intern Med, 2021, 289(3):268-292. doi: 10.1111/joim.13169
[8]	Silvetti E, Lanza O, Romeo F, et al. The pivotal role of ECG in cardiomyopathies[J]. Front Cardiovasc Med, 2023, 10: 1178163. doi: 10.3389/fcvm.2023.1178163
[9]	宋爽. 临床诊断AL型心肌淀粉样变性的影像学特征分析 [D]. 2020. 长春: 吉林大学.
	Song S. Analysis imaging features of amyloid light chain myocardial amyloidosis diagnosed clinically [D]. 2020. Changchun: Jilin University.
[10]	Slivnick JA, Wallner AL, Vallakati A, et al. Indexed left ventricular mass to QRS voltage ratio is associated with heart failure hospitalizations in patients with cardiac amyloidosis[J]. Int J Cardiovasc Imaging, 2021, 37(3):1043-1051. doi: 10.1007/s10554-020-02059-1
[11]	Dominguez F. Predicting pacemaker implantation in cardiac amyloidosis: let's start with an ECG[J]. Eur J Heart Fail, 2022, 24(7):1237-1238. doi: 10.1002/ejhf.2591
[12]	Boldrini M, Cappelli F, Chacko L, et al. Multiparametric echocardiography scores for the diagnosis of cardiac amyloidosis[J]. JACC Cardiovasc Imaging, 2020, 13(4):909-920. doi: 10.1016/j.jcmg.2019.10.011
[13]	Liang S, Liu Z, Li Q, et al. Advance of echocardiography in cardiac amyloidosis[J]. Heart Fail Rev, 2023, 28(6):1345-1356. doi: 10.1007/s10741-023-10332-3
[14]	Damy T, Costes B, Hagège AA, et al. Prevalence and clinical phenotype of hereditary transthyretin amyloid cardiomyopathy in patients with increased left ventricular wall thickness[J]. Eur Heart J, 2016, 37(23):1826-1834. doi: 10.1093/eurheartj/ehv583
[15]	AbouEzzeddine OF, Davies DR, Scott CG, et al. Prevalence of transthyretin amyloid cardiomyopathy in heart failure with preserved ejection fraction[J]. JAMA Cardiol, 2021, 6(11):1267-1274. doi: 10.1001/jamacardio.2021.3070
[16]	Hotta VT, Giorgi MCP, Fernandes F, et al. Cardiac amyloidosis: non-invasive diagnosis[J]. Rev Assoc Med Bras (1992), 2020, 66(3):345-352. doi: 10.1590/1806-9282.66.3.345
[17]	Stricagnoli M, Cameli M, Incampo E, et al. Speckle tracking echocardiography in cardiac amyloidosis[J]. Heart Fail Rev, 2019, 24(5):701-707. doi: 10.1007/s10741-019-09796-z
[18]	Scheel PJ 3rd, Mukherjee M, Hays AG, et al. Multimodality imaging in the evaluation and prognostication of cardiac amyloidosis[J]. Front Cardiovasc Med, 2022, 9: 787618. doi: 10.3389/fcvm.2022.787618
[19]	Lei C, Zhu X, Hsi DH, et al. Predictors of cardiac involvement and survival in patients with primary systemic light-chain amyloidosis: roles of the clinical, chemical, and 3-D speckle tracking echocardiography parameters[J]. BMC Cardiovasc Disord, 2021, 21(1):43. doi: 10.1186/s12872-021-01856-3
[20]	Dorbala S, Cuddy S, Falk RH. How to image cardiac amyloidosis: a practical approach[J]. JACC Cardiovasc Imaging, 2020, 13(6):1368-1383. doi: 10.1016/j.jcmg.2019.07.015
[21]	Hou W, Wang Z, Huang J, et al. Early diagnostic and prognostic value of myocardial strain derived from cardiovascular magnetic resonance in patients with cardiac amyloidosis[J]. Cardiovasc Diagn Ther, 2023, 13(6):979-993. doi: 10.21037/cdt-23-205
[22]	Yilmaz A. Interpretation of CMR-based mapping findings in cardiac amyloidosis: please act with caution[J]. JACC Cardiovasc Imaging, 2022, 15(4):604-606. doi: 10.1016/j.jcmg.2021.12.006
[23]	Sanchorawala V. Systemic light chain amyloidosis[J]. N Engl J Med, 2024, 390(24):2295-2307. doi: 10.1056/NEJMra2304088
[24]	Wan K, Sun J, Han Y, et al. Increased prognostic value of query amyloid late enhancement score in light-chain cardiac amyloidosis[J]. Circ J, 2018, 82(3):739-746. doi: 10.1253/circj.CJ-17-0464
[25]	Lin L, Li X, Feng J, et al. The prognostic value of T1 mapping and late gadolinium enhancement cardiovascular magnetic resonance imaging in patients with light chain amyloidosis[J]. J Cardiovasc Magn Reson, 2018, 20(1):2. doi: 10.1186/s12968-017-0419-6
[26]	Briasoulis A, Lama N, Rempakos A, et al. Diagnostic and prognostic value of non-late gadolinium enhancement cardiac magnetic resonance parameters in cardiac amyloidosis[J]. Curr Probl Cardiol, 2023, 48(4):101573. doi: 10.1016/j.cpcardiol.2022.101573
[27]	Baggiano A, Boldrini M, Martinez-Naharro A, et al. Noncontrast magnetic resonance for the diagnosis of cardiac amyloidosis [J]. JACC Cardiovasc Imaging, 2020, 13(1 Pt 1):69-80.
[28]	Martinez-Naharro A, Kotecha T, Norrington K, et al. Native T1 and extracellular volume in transthyretin amyloidosis[J]. JACC Cardiovasc Imaging, 2019, 12(5):810-819. doi: 10.1016/j.jcmg.2018.02.006
[29]	Dorbala S, Kijewski MF. Molecular imaging of systemic and cardiac amyloidosis: recent advances and focus on the future[J]. J Nucl Med, 2023, 64(Suppl 2):20S-28S.
[30]	中华医学会心血管病学分会心力衰竭学组, 中华心血管病杂志编辑委员会. 转甲状腺素蛋白心脏淀粉样变诊断与治疗中国专家共识[J]. 中华心血管病杂志, 2021, 49(4):324-332.
	Heart Failure Group of Chinese Society of Cardiology, Editorial Board of Chinese Journal of Cardiology. Chinese expert consensus on the diagnosis and treatment of transthyretin cardiac amyloidosis[J]. Chin J Cardiol, 2021, 49(4):324-332.
[31]	Clerc OF, Vijayakumar S, Dorbala S. Radionuclide imaging of cardiac amyloidosis: an update and future aspects[J]. Semin Nucl Med, 2024, 54(5):717-732. doi: 10.1053/j.semnuclmed.2024.05.012
[32]	Gillmore JD, Maurer MS, Falk RH, et al. Nonbiopsy diagnosis of cardiac transthyretin amyloidosis[J]. Circulation, 2016, 133(24):2404-2412. doi: 10.1161/CIRCULATIONAHA.116.021612
[33]	王雪竹, 任超, 黄政海, 等. 核医学显像在系统性轻链型淀粉样变诊疗中的应用进展[J]. 中华核医学与分子影像杂志, 2022, 42(4):243-247. doi: 10.3760/cma.j.cn321828-20201012-00369
	Wang XZ, Ren C, Huang ZH, et al. Advances in the application of nuclear medicine imaging in the diagnosis and treatment of systematic light chain amyloidosis[J]. Chin J Nucl Med Mol Imaging, 2022, 42(4):243-247. doi: 10.3760/cma.j.cn321828-20201012-00369
[34]	Vergaro G, Aimo A, Barison A, et al. Keys to early diagnosis of cardiac amyloidosis: red flags from clinical, laboratory and imaging findings[J]. Eur J Prev Cardiol, 2020, 27(17):1806-1815. doi: 10.1177/2047487319877708
[35]	Arvanitis M, Koch CM, Chan GG, et al. Identification of transthyretin cardiac amyloidosis using serum retinol-binding protein 4 and a clinical prediction model[J]. JAMA Cardiol, 2017, 2(3):305-313. doi: 10.1001/jamacardio.2016.5864
[36]	Gillmore JD, Damy T, Fontana M, et al. A new staging system for cardiac transthyretin amyloidosis[J]. Eur Heart J, 2018, 39(30):2799-2806. doi: 10.1093/eurheartj/ehx589
[37]	Argon A, Nart D, Yilmazbarbet F. Cardiac amyloidosis: clinical features, pathogenesis, diagnosis, and treatment[J]. Turk Patoloji Derg, 2024, 40(1):1-9.